CN1752088A - 含有替莫唑胺酯的药用组合物 - Google Patents

含有替莫唑胺酯的药用组合物 Download PDF

Info

Publication number
CN1752088A
CN1752088A CNA2004100720564A CN200410072056A CN1752088A CN 1752088 A CN1752088 A CN 1752088A CN A2004100720564 A CNA2004100720564 A CN A2004100720564A CN 200410072056 A CN200410072056 A CN 200410072056A CN 1752088 A CN1752088 A CN 1752088A
Authority
CN
China
Prior art keywords
temozolomide
carboxylate
ester
methyl
hexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004100720564A
Other languages
English (en)
Chinese (zh)
Inventor
王永峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Tasly Group Co Ltd
Original Assignee
Tianjin Tasly Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Tasly Group Co Ltd filed Critical Tianjin Tasly Group Co Ltd
Priority to CNA2004100720564A priority Critical patent/CN1752088A/zh
Priority to HK07108352.8A priority patent/HK1100440B/en
Priority to MX2007003366A priority patent/MX2007003366A/es
Priority to PL05785075T priority patent/PL1798234T3/pl
Priority to DK05785075.2T priority patent/DK1798234T3/da
Priority to US11/575,849 priority patent/US7579336B2/en
Priority to KR1020077009054A priority patent/KR101065984B1/ko
Priority to EP05785075A priority patent/EP1798234B1/en
Priority to ES05785075T priority patent/ES2389376T3/es
Priority to NZ554609A priority patent/NZ554609A/en
Priority to AU2005287799A priority patent/AU2005287799B2/en
Priority to UAA200704418A priority patent/UA89795C2/ru
Priority to BRPI0515555-0A priority patent/BRPI0515555A/pt
Priority to JP2007532748A priority patent/JP5620046B2/ja
Priority to CA2580910A priority patent/CA2580910C/en
Priority to RU2007114948/04A priority patent/RU2393160C2/ru
Priority to PCT/CN2005/001477 priority patent/WO2006032190A1/zh
Priority to ARP050103949A priority patent/AR050947A1/es
Priority to MYPI20054428A priority patent/MY153713A/en
Publication of CN1752088A publication Critical patent/CN1752088A/zh
Priority to IL182027A priority patent/IL182027A/en
Priority to ZA200702801A priority patent/ZA200702801B/xx
Priority to JP2012209183A priority patent/JP2013028630A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004100720564A 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物 Pending CN1752088A (zh)

Priority Applications (22)

Application Number Priority Date Filing Date Title
CNA2004100720564A CN1752088A (zh) 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物
BRPI0515555-0A BRPI0515555A (pt) 2004-09-22 2005-09-15 composição farmacêutica compreendendo éster de temozolomida
UAA200704418A UA89795C2 (ru) 2004-09-22 2005-09-15 Фармацевтическая композиция, которая содержит эстер темозоломида
PL05785075T PL1798234T3 (pl) 2004-09-22 2005-09-15 Kompozycja farmaceutyczna zawierająca ester temozolomidu
DK05785075.2T DK1798234T3 (da) 2004-09-22 2005-09-15 Farmaceutisk sammensætning omfattende temozolomidester
US11/575,849 US7579336B2 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
KR1020077009054A KR101065984B1 (ko) 2004-09-22 2005-09-15 테모졸로마이드 에스테르를 포함하는 약학 조성물
EP05785075A EP1798234B1 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
JP2007532748A JP5620046B2 (ja) 2004-09-22 2005-09-15 テモゾロマイドエステルよりなる医薬組成物
MX2007003366A MX2007003366A (es) 2004-09-22 2005-09-15 Composicion farmaceutica que comprende un ester de temozolomida.
AU2005287799A AU2005287799B2 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
HK07108352.8A HK1100440B (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
NZ554609A NZ554609A (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
ES05785075T ES2389376T3 (es) 2004-09-22 2005-09-15 Composición farmacéutica que comprende ester de temozolomida
CA2580910A CA2580910C (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
RU2007114948/04A RU2393160C2 (ru) 2004-09-22 2005-09-15 Фармацевтическая композиция, содержащая эфир темозоломида
PCT/CN2005/001477 WO2006032190A1 (en) 2004-09-22 2005-09-15 Pharmaceutical composition comprising temozolomide ester
ARP050103949A AR050947A1 (es) 2004-09-22 2005-09-21 Derivados de 3,4-dihidro-3-metil-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazina-8-carboxilato
MYPI20054428A MY153713A (en) 2004-09-22 2005-09-22 A pharmaceutical composition comprising 3, 4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-1,2,3,5-tetrazine-8-carboxylate
IL182027A IL182027A (en) 2004-09-22 2007-03-19 Pharmaceutical composition comprising tamoxolomide ester and the method of preparation thereof
ZA200702801A ZA200702801B (en) 2004-09-22 2007-04-03 Pharmaceutical composition comprising temozolomide ester
JP2012209183A JP2013028630A (ja) 2004-09-22 2012-09-24 テモゾロマイドエステルよりなる医薬組成物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA2004100720564A CN1752088A (zh) 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物

Publications (1)

Publication Number Publication Date
CN1752088A true CN1752088A (zh) 2006-03-29

Family

ID=36089840

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100720564A Pending CN1752088A (zh) 2004-09-22 2004-09-22 含有替莫唑胺酯的药用组合物

Country Status (20)

Country Link
US (1) US7579336B2 (https=)
EP (1) EP1798234B1 (https=)
JP (2) JP5620046B2 (https=)
KR (1) KR101065984B1 (https=)
CN (1) CN1752088A (https=)
AR (1) AR050947A1 (https=)
AU (1) AU2005287799B2 (https=)
BR (1) BRPI0515555A (https=)
CA (1) CA2580910C (https=)
DK (1) DK1798234T3 (https=)
ES (1) ES2389376T3 (https=)
IL (1) IL182027A (https=)
MX (1) MX2007003366A (https=)
MY (1) MY153713A (https=)
NZ (1) NZ554609A (https=)
PL (1) PL1798234T3 (https=)
RU (1) RU2393160C2 (https=)
UA (1) UA89795C2 (https=)
WO (1) WO2006032190A1 (https=)
ZA (1) ZA200702801B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1727340B (zh) * 2004-07-29 2011-05-18 天津帝士力投资控股集团有限公司 一种替莫唑胺-8-羧酸酯及其组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808173A1 (en) * 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
US8558511B2 (en) * 2009-04-07 2013-10-15 Battelle Memorial Institute Method and apparatus for smart battery charging including a plurality of controllers each monitoring input variables
KR20140087846A (ko) * 2012-12-31 2014-07-09 주식회사 삼양바이오팜 테모졸로미드를 포함하는 안정성이 개선된 약제학적 조성물 및 이의 제조방법
RU2527258C1 (ru) * 2013-02-19 2014-08-27 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" 6-ЗАМЕЩЕННЫЕ 3-АЗОЛИЛИМИДАЗО[1,2-b][1,2,4,5]ТЕТРАЗИНЫ, ПРОЯВЛЯЮЩИЕ ПРОТИВООПУХОЛЕВУЮ АКТИВНОСТЬ
US10709715B2 (en) * 2017-12-03 2020-07-14 Cipla Limited Method of treating hypertension
EP3833342A4 (en) * 2018-08-09 2022-07-13 The Board of Trustees of the University of Illinois IMIDAZOTETRAZINE COMPOUNDS
CN114014862A (zh) * 2021-06-28 2022-02-08 烟台大学 一种治疗脑胶质瘤的新化合物及其制备和应用
CN116947765B (zh) * 2022-06-23 2025-10-10 北京新源医疗有限责任公司 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616125D0 (en) * 1986-07-02 1986-08-06 May & Baker Ltd Compositions of matter
UA29466C2 (uk) * 1993-01-14 2000-11-15 Канзер Рісерч Кампейн Технолоджі, Лтд Фармацевтична композиція з антипухлинною активністю
CN1244583C (zh) * 2002-09-29 2006-03-08 天津天士力集团有限公司 替莫唑胺－8－羧酸脂和－8－酰胺衍生物，它们的合成方法以及它们在制备抗癌制剂中的应用
CN1742723A (zh) * 2004-09-02 2006-03-08 天津倍方科技发展有限公司 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1727340B (zh) * 2004-07-29 2011-05-18 天津帝士力投资控股集团有限公司 一种替莫唑胺-8-羧酸酯及其组合物

Also Published As

Publication number Publication date
CA2580910C (en) 2011-10-25
UA89795C2 (ru) 2010-03-10
AU2005287799B2 (en) 2009-03-26
EP1798234A1 (en) 2007-06-20
US20080044457A1 (en) 2008-02-21
EP1798234A4 (en) 2009-04-29
JP2013028630A (ja) 2013-02-07
ZA200702801B (en) 2008-08-27
BRPI0515555A (pt) 2008-07-29
MX2007003366A (es) 2008-03-05
AR050947A1 (es) 2006-12-06
PL1798234T3 (pl) 2012-11-30
US7579336B2 (en) 2009-08-25
KR101065984B1 (ko) 2011-09-19
HK1100440A1 (en) 2007-09-21
AU2005287799A1 (en) 2006-03-30
NZ554609A (en) 2010-06-25
DK1798234T3 (da) 2012-08-27
CA2580910A1 (en) 2006-03-30
KR20070062569A (ko) 2007-06-15
JP2008513523A (ja) 2008-05-01
JP5620046B2 (ja) 2014-11-05
IL182027A0 (en) 2007-07-24
ES2389376T3 (es) 2012-10-25
MY153713A (en) 2015-03-13
WO2006032190A1 (en) 2006-03-30
RU2393160C2 (ru) 2010-06-27
RU2007114948A (ru) 2008-10-27
IL182027A (en) 2014-05-28
EP1798234B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
US20240166652A1 (en) Modulators of the integrated stress pathway
US10538502B2 (en) Tricyclic spiro compound
US20240018133A1 (en) Modulators of the integrated stress pathway
CN1575289A (zh) 6－羟基异黄酮、及其衍生物和相关药物
CN1087911A (zh) 雷怕霉素衍生物
CN1694867A (zh) 口服固体药用晶体及治疗排尿困难的包含它的口服固体药
CN1331693A (zh) 1,2－稠合的喹啉衍生物
CN1184475A (zh) 具有mdr活性的四氢化萘化合物
CN1062291A (zh) 药物
JP2013028630A (ja) テモゾロマイドエステルよりなる医薬組成物
CA3119912A1 (en) A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
CN85101761A (zh) 新型色胺衍生物的制备方法和应用
CN1411447A (zh) 赛利可喜的多态晶型
WO2020262603A1 (ja) Ｅｐ２アンタゴニスト
CN101065127A (zh) 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途
CN1090633C (zh) 叶绿素a降解产物金属络合物、其制备方法及抗胃溃疡药物
CN1644208A (zh) 石杉碱甲、乙复合成分的蛇足石杉提取物及其制备方法
CN1073936A (zh) α-取代的苯甲胺衍生物
CN1727332A (zh) 芳甲氨基二硫代甲酸酯类化合物及其制备方法和应用
CN1628662A (zh) 具有镇痛作用的药物
CN1891701A (zh) 杂芳环缩氨基硫脲类化合物及其衍生物和它们在制备抗肿瘤药物中的应用
CN1727340A (zh) 一种替莫唑胺－8－羧酸酯及其组合物
JP2023512413A (ja) ジヒドロオロト酸デヒドロゲナーゼの阻害のための方法および組成物
CN1073942A (zh) 杂环取代的苯甲胺衍生物
CN1098258C (zh) 异香豆素衍生物及其在医药上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication